The estimated Net Worth of Steven L. Hoerter is at least 12.2 百万$ dollars as of 12 December 2023. Mr. Hoerter owns over 30,664 units of Deciphera Pharmaceuticals Inc stock worth over 1,862,005$ and over the last 13 years he sold DCPH stock worth over 1,328,108$. In addition, he makes 9,025,190$ as President、 Chief Executive Officer、 Director at Deciphera Pharmaceuticals Inc.
Steven has made over 25 trades of the Deciphera Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 30,664 units of DCPH stock worth 471,306$ on 12 December 2023.
The largest trade he's ever made was selling 30,664 units of Deciphera Pharmaceuticals Inc stock on 12 December 2023 worth over 471,306$. On average, Steven trades about 3,632 units every 69 days since 2012. As of 12 December 2023 he still owns at least 72,763 units of Deciphera Pharmaceuticals Inc stock.
You can see the complete history of Mr. Hoerter stock trades at the bottom of the page.
Steven L. Hoerter serves as President, Chief Executive Officer, Director of the Company. Mr. Hoerter has served as our President and Chief Executive Officer since March 2019 and has been a member of our Board of Directors since May 2018. Prior to joining us, Mr. Hoerter served as Chief Commercial Officer for Agios Pharmaceuticals, Inc., a pharmaceutical company, from February 2016 to March 2019. From September 2018 through the present, Mr. Hoerter has served on the board of directors of Constellation Pharmaceuticals, Inc., a biotechnology company, and from December 2016 to February 2018, Mr. Hoerter served on the board of directors of Ignyta, Inc., a biopharmaceutical company. From August 2011 to March 2015, Mr. Hoerter served as Senior Vice President, Commercial and from March 2015 to February 2016, as Executive Vice President and Chief Commercial Officer at Clovis Oncology, Inc., a biopharmaceutical company. Before joining Clovis in August 2011, he was General Manager and Management Center Head at Roche, a pharmaceutical company, for the Sub-Saharan Africa and Indian Ocean Region. From 2005 to 2010, Mr. Hoerter held a variety of positions at Genentech, Inc., a biotechnology company. Prior to that, Mr. Hoerter held commercial roles at Chiron Corporation, a biopharmaceutical company, and Eli Lilly and Company, a pharmaceutical company, in the U.S., Europe and Africa. Mr. Hoerter received his B.A. from Bucknell University, M.B.A. from Tilburg University and M.S. in management from Purdue University.
As the President、 Chief Executive Officer、 Director of Deciphera Pharmaceuticals Inc, the total compensation of Steven Hoerter at Deciphera Pharmaceuticals Inc is 9,025,190$. There are no executives at Deciphera Pharmaceuticals Inc getting paid more.
Steven Hoerter is 49, he's been the President、 Chief Executive Officer、 Director of Deciphera Pharmaceuticals Inc since 2019. There are 17 older and 2 younger executives at Deciphera Pharmaceuticals Inc. The oldest executive at Deciphera Pharmaceuticals Inc is Edward Benz, 73, who is the Independent Director.
Steven's mailing address filed with the SEC is C/O ORIC PHARMACEUTICALS, INC., 240 E. GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over 25,274,872$ worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth 57,831,028$ . The most active insiders traders include Liam Ratcliffe、Associates Llc Brightstar、Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of 1,218,775$. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth 47,016$.
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include: